Cha Biotech Secures 100 Billion Won Investment from Hanwha General Insurance and Hanwha Life Insurance
Promoting Convergence of Digital Healthcare and Financial Sectors
Cha Biotech has secured a total investment of 100 billion won from Hanwha General Insurance and Hanwha Life Insurance.
Cha Biotech announced on January 16 that Hanwha General Insurance and Hanwha Life Insurance participated in its third-party paid-in capital increase. The investment amounts to 70 billion won from Hanwha General Insurance and 30 billion won from Hanwha Life Insurance.
The company explained that this investment is part of a collaboration to promote the convergence of insurance and healthcare businesses by combining Cha Bio Group's medical and biotechnology expertise, as well as its artificial intelligence (AI) and data-driven digital healthcare capabilities, with the infrastructure of Hanwha’s financial and insurance companies.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Both parties will jointly develop health management programs for insurance customers and AI- and data-based health monitoring services. They will also gradually identify new business models that link overseas insurance with healthcare.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.